If You Invested $10,000 In Pfizer Stock 10 Years Ago, How Much Would You Have Now?

Pfizer Inc. PFE discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally.

It is set to report its Q4 2024 earnings on Feb. 4, before the market opens. Wall Street analysts expect the company to post EPS of $0.46, up from $0.10 in the year-ago period. According to Benzinga Pro, quarterly revenue is expected to reach $17.13 billion, up from $14.25 billion  the year before.

Don't Miss:

• Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing — you can become an investor for $0.80 per share today.
• Arrived Home's Private Credit Fund’s has historically paid an annualized dividend yield of 8.1%*, which provides access to a pool of short-term loans backed by residential real estate with just a $100 minimum. 

If You Bought Pfizer Stock 10 Years Ago

The company's stock traded at approximately $30.20 per share 10 years ago. If you had invested $10,000, you could have bought roughly 331 shares. Currently, shares trade at $26.75, meaning your investment's value could have declined to $8,858 from stock price depreciation. However, Pfizer also paid dividends during these 10 years. 

Pfizer's dividend yield is currently 6.43%. Over the last 10 years, it has paid about $16.86 in dividends per share, which means you could have made $5,582 from dividends alone. 

Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. You can invest today for just $0.26/share with a $1000 minimum.

Summing up $8,858 and $5,582, we end up with the final value of your investment, which is $14,440. This is how much you could have made if you had invested $10,000 in Pfizer stock 10 years ago. This means a total return of 44.4%. However, this figure is significantly below the S&P 500 total return for the same period, which was 240.80%.

What Could The Next 10 Years Bring? 

Pfizer has a consensus rating of "Neutral" and a price target of $36.74 based on the ratings of 24 analysts. The price target implies more than 37% potential upside from the current stock price.

On Oct. 29, the company announced its Q3 2024 earnings, posting adjusted EPS of $1.06, swinging from a per-share loss of $0.17 a year earlier, beating the consensus of $0.62, as reported by Benzinga. 

See Also: This Jeff Bezos-backed startup will allow you to become a landlord in just 10 minutes, with minimum investments as low as $100.

The drugmaker reported sales of $17.70 billion, up 31% year-over-year (up 32% operationally), beating the consensus of $14.95 billion. 

Pfizer updated its 2024 revenue forecast to $61 billion-$64 billion, compared with prior guidance of $59.5 billion-$62.5 billion and consensus of $61.16 billion.

Pfizer Expects 2024 adjusted EPS of $2.75-$2.95, compared with prior guidance of $2.45-$2.65 and consensus of $2.65.

Check out this article by Benzinga for six analysts' insights on Pfizer.

Given the expected upside potential of 37%, growth-focused investors may find Pfizer stock attractive. Furthermore, they can benefit from the company's solid dividend yield of 6.43% and consistent hikes. Pfizer has raised its dividend consecutively for the last 15 years.

Wondering if your investments can get you to a $5,000,000 nest egg? Speak to a financial advisor today. SmartAsset’s free tool matches you up with up to three vetted financial advisors who serve your area, and you can interview your advisor matches at no cost to decide which one is right for you.

Arrived Achieved A Total Return of 34.7% On Their Biggest Sale Yet — Diversify Your Monthly Income Stream With Fractional Real Estate

Arrived allows individuals to invest in shares of rental properties for as little as $100, providing the potential for monthly rental income and long-term appreciation without the hassles of being a landlord. With over $1 million in dividends paid out last quarter and a growing selection of properties across various markets, Arrived offers an attractive alternative for investors seeking to build a diversified real estate portfolio. 

In October 2024, Arrived sold The Centennial, achieving a total return of 34.7% (11.2% average annual returns) for investors. Arrived aims to continue delivering similar value across our portfolio through careful market selection, attentive property management, and thoughtful timing in sales.

Looking for fractional real estate investment opportunities? The Benzinga Real Estate Screener features the latest offerings.